Replies to post #139784 on Biotech Values

[iwfal]

It’s a four-drug cocktail if you count ritonavir.

My bad! I completely missed that "nuance" - and just for sake of comparison, I would guesstimate that SOC plus Ritonavir plus DAA get similar rates of efficacy?

http://www.prnewswire.com/news-releases/intermune-reports-virologic-response-of-ritonavir-boosted-danoprevir-rg7227itmn-191-in-patients-with-chronic-hepatitis-c-90949624.html

(Given that it contains SOC I would guess that the above protocol has typical rates of breakthrough etc)

[iwfal]

SAE of ritonavir since the Abbott combo is the hot conversation:

The common SAE (although severity unclear):

1) nausea in about 25 pct of patients
2) diarrhea in about 15%
3) vomitting in about 15%.

The less common (but more severe) SAE:

Liver tox - sometimes severe. FDA label states probably a result of drug interactions, but is not assured on this topic.

Exacerbation of T2D


Drug interactions:

1)Large number of interactions since ritonavir interferes with common liver drug metabolism pathway. And I'd note that, unlike HIV, which was mostly younger patients, the HCV patient population is likely to be older (in the developed world) and thus a large fraction of the HCV population will be on some of these other drugs.

FDA Label is here